Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic

Authors

  • J Bolodeoku Lipid Clinic, Department of Cardiology, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire RG24 9NA
  • T Gbaa Lipid Clinic, Department of Cardiology, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire RG24 9NA
  • K Morris Department of Clinical Biochemistry, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire RG24 9NA
  • S Whitehead Department of Clinical Biochemistry, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire RG24 9NA

DOI:

https://doi.org/10.14738/bjhmr.106.15955

Keywords:

LDL-cholesterol, PCSK9 Inhibitors, Alirocumab, Evolocumab, Secondary care lipid clinic, Monoclonal antibodies

Abstract

Proprotein convertase subtilisin kexin type 9 (PCSK9) is an essential regulator of cholesterol metabolism. It was introduced as a monoclonal antibody to regulate LDL-R by recycling more LDLR onto the cell's surface. The clinically available PCSK9 monoclonal antibodies are alirocumab and evolocumab. This audit-based assessment aims to evaluate the impact of PCSK9 inhibitors on patient outcomes in achieving the European Atherosclerosis Society (EAS) recommended target for low-density lipoprotein cholesterol (LDL-C) levels (<1.8mmol/l) within a secondary care lipid clinic.

Downloads

Published

2023-12-17

How to Cite

Bolodeoku, J., Gbaa, T., Morris, K., & Whitehead, S. (2023). Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of &lt; 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic. British Journal of Healthcare and Medical Research, 10(6), 91–102. https://doi.org/10.14738/bjhmr.106.15955

Issue

Vol. 10 No. 6 (2023): British Journal of Healthcare and Medical Research

Section

Original Articles

License

Copyright (c) 2023 J Bolodeoku, T Gbaa, K Morris, S Whitehead

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.